David Miller

David Miller is a partner in HOFFMANN EITLE’s biotechnology practice group.  His practice has given him experience in a broad range of technical fields, including antibody technology, ADC technology, nucleic-acid and liposome-based medicines, protein and peptide-based medicines, vaccine technology, biologic production and diagnostic assays.  

David has a large prosecution practice before the EPO and coordinates complex portfolios for both early-stage and late-stage products.  He also has extensive experience in opposition proceedings at the European Patent Office (EPO), and has defended patents protecting products such as Imbruvica® (ibrutinib), Kadcyla® (trastuzumab emtansine), Lemtrada® (alemtuzumab), Eloctate® (recombinant Factor VIII) and Alprolix® (recombinant Factor IX).

Other aspects of David’s practice include drafting, IP due diligence, and FTO analyses.  In addition to patent matters, David manages a number of SPC portfolios and regularly advises on complex aspects of SPC law.  He also has significant experience in respect of paediatric extensions, orphan drug protection and marketing exclusivity.

Before entering the patent profession, David obtained a degree in natural sciences from the University of Cambridge, as well as a degree in the management of intellectual property from the University of London.  He qualified as a European Patent Attorney and a Chartered Patent Attorney in 2009.  David joined HOFFMANN EITLE in 2023 after eight years as a partner at another top-tier firm.